Vida Ventures Advisors, LLC

Est. AUM

$29.37B

13F long equity, this entity only

Positions

Period

Sep 2025 (Q3)

SEC EDGAR

Sep 2025 (Q3)

#	Issuer	Class	Value	Shares	% Portfolio	Discretion
1	KYVERNA THERAPEUTICS INC	COM	$27.14B	4523924	92.41%	SOLE
2	ALLOGENE THERAPEUTICS INC	COM	$2.23B	1798163	7.59%	SOLE

Values in USD (reported in $thousands on 13F). Source: SEC EDGAR.